Table 3.
Demographic and clinical parameters in the cerebrospinal fluid and serum in men and women.
| Parameters | PD | Control | ||
|---|---|---|---|---|
| Men (n = 18) | Women (n = 16) | Men (n = 13) | Women (n = 17) | |
| Age, years | 63.2 ± 10 | 62.1 ± 12 | 56.9 ± 15 | 584 ± 12 |
| Body mass index, kg/m2 | 23.1 ± 7 | 23.3 ± 3 | 24.4 ± 5 | 24.9 ± 3 |
| Education, years | 17.3 ± 1.3 | 17.4 ± 1.7 | 17.5 ± 4 | 17.3 ± 3 |
| Albumin index | 6.8 ± 1.6 | 7.0 ± 2 | 6.7 ± 1.5 | 6.5 ± 1.8 |
| Leukocyte count, cells/µL | 3.1 ± 0.6 | 3.2 ± 0.8 | 2.8 ± 0.5 | 2.6 ± 0.7 |
| CSF MPO content, pg/mL | 148 ± 63 * | 81 ± 71 | 99 ± 41 | 103 ± 47 |
| CSF MPO activity, mU/mL | 0.0294 ± 0.001 | 0.0287 ± 0.001 | 0.0286 ± 0.001 | 0.0294 ± 0.001 |
| Serum MPO content, pg/mL | 3890 ± 3100 * | 3690 ± 1695 ** | 1242 ± 727 | 1650 ± 608 |
| Serum MPO activity, mU/mL | 44.3 ± 3 ** | 43.7 ± 4 ** | 35.1 ± 6 | 35 ± 6 |
| CSF AOPP content, µM | 16.7 ± 23 (n = 6) | 9.9 ± 19 (n = 10) | nd | nd |
| Serum AOPP content, µM | 588 ± 311 | 455 ± 391 | nd | nd |
| Levodopa equivalent daily dose, mg | 714 ± 664 | 650 ± 432 | ||
| Disease duration, years | 11 ± 8 | 12 ± 8 | ||
| Age at PD onset, years | 51.4 ± 13 | 53.7 ± 15 | ||
| Modified Hoehn–Yahr stage | 2.2 ± 0.7 | 2.1 ± 0.8 | ||
| Modified Schwab–England | 76.5 ± 23 | 68.8 ± 27 | ||
| MDS-UPDRS part III (on) | 29.4 ± 14 | 23.8 ± 17 | ||
| Total MDS-UPDRS (I-III) (on) | 44 ± 26 | 37.2 ± 30 | ||
| MDS-UPDRS part IV (all patients) | 1.4 ± 2.5 | 1.5 ± 2.2 | ||
Mean ± SD. Statistical comparisons were carried out with the χ2 test (dichotomous variables) or the Student’s t-test (quantitative variables). * p < 0.01 versus PD women, ** p < 0.001 versus the corresponding control group. Abbrev.: AOPP, advanced oxidation protein products; CSF, cerebrospinal fluid; MDS-UPDRS, International Parkinson and Movement Disorder Society-Sponsored revision of the Unified Parkinson’s Disease Rating Scale; MPO, myeloperoxidase; nd, nondetectable; NS, no significant; PD, Parkinson’s disease.